Recent Updates
Recently added Catalysts
ATYR Negative Sentiment Score: 20/100

ATYR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against aTyr Pharma, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against aTyr Pharma, Inc. regarding misleading statements made during the class period of January 16, 2025, to September 12, 2025. The allegations focus on claims that the company misrepresented the efficacy of its drug, Efzofitimod, particularly in relation to tapering steroid use. Investors affected by these alleged misstatements are encouraged to contact the law firm for potential legal recourse. The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 8, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against aTyr Pharma, alleging misleading statements regarding Efzofitimod's efficacy.
  • The complaint claims that aTyr's management provided overly positive outlooks on the drug while failing to disclose critical facts.
  • Investors may have purchased shares at artificially inflated prices due to misrepresentations by the company.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In aTyr (ATYR) To Contact Him Directly To Discuss Their Options
If you purchased or acquired aTyr common stock between January 16, 2025, and September 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ:ATYR) in the United States District Court for the Southern District of California on behalf of all persons and entities who purchased or otherwise acquired aTyr common stock between January 16, 2025, and September 12, 2025, both dates inclusive (the “Class Period”).
Investors have until December 8, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Defendants provided overwhelmingly positive statements to investors regarding the efficacy of Efzofitimod; (2) At the same time, Defendants disseminated false and misleading statements and/or concealed material adverse facts concerning the drug's actual capability-particularly its ability to enable patients to completely taper their steroid usage; and (3) As a result of these omissions and misrepresentations, Plaintiff and other shareholders purchased aTyr's securities at artificially inflated prices.
If you purchased or otherwise acquired aTyr shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who should contact Bragar Eagel & Squire regarding aTyr?

Investors who purchased aTyr stock between January 16, 2025, and September 12, 2025.

What legal action is being taken against aTyr Pharma?

A class action lawsuit has been filed in the U.S. District Court for the Southern District of California.

What are the allegations in the aTyr lawsuit?

The lawsuit claims aTyr made false statements about the drug Efzofitimod and misled investors.

What is the deadline to apply as lead plaintiff?

Investors have until December 8, 2025, to apply to the Court.

How can investors get more information about their rights?

They can contact Brandon Walker or Marion Passmore at Bragar Eagel & Squire.

Last updated: Oct 14, 2025